eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in UK.

Eliquis (apixaban) for prevention of stroke / systemic embolism in patients with NVAF

ELIQUIS: An oral, direct factor Xa inhibitor indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).1

ELIQUIS has been compared with warfarin in a phase III trial for the prevention of stroke and systemic embolism in patients with NVAF.2

Learn more about the ARISTOTLE trial.

ELIQUIS is the only NOAC to be compared with a pre-specified aspirin treatment arm in a phase III trial in patients with NVAF considered unsuitable for warfarin.3

Learn more about the AVERROES trial.

ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
AVERROES = ApixabanVersus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment

ELIQUIS SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflets.

References:

  1. ELIQUIS (apixaban) Summary of Product Characteristics
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.
  3. Connolly SJ et al. N Engl J Med 2011; 364: 806–817.